BI 836845 in Estrogen Receptor Positive Metastatic Breast Cancer

NCT02123823 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

164

Enrollment

INDUSTRY

Sponsor class

Conditions

Neoplasms

Interventions

DRUG: Everolimus
DRUG: Exemestane
DRUG: BI 836845

Sponsor

Boehringer Ingelheim